COVID-19

Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update

Conference Call/Webcast Scheduled for Today at 4:30 PM ETSTONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA…

1 year ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised…

1 year ago

Ainos Celebrates First Listing Anniversary on Nasdaq

Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipelineSAN DIEGO,…

1 year ago

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell…

1 year ago

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapiesHINGHAM, Mass., Aug.…

1 year ago

PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute

PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in AustraliaVANCOUVER, British Columbia, Aug. 10,…

1 year ago

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the…

1 year ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene®…

1 year ago

Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company –…

1 year ago

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call…

1 year ago